Jeff Arnold: I don’t think it’s a change. I think it’s an improvement. Yeah, so we are basically saying that, we have done the strategic review and affirm that, yes, enterprise is the core and we are doing really well there, and we need to double down there. And we have affirmed that there’s a market for Provider, and it’s easier to detach from Sharecare and we think we could maintain data rights, which is why we are in the business to start with. And then we are getting that more profitable too, because we have started this major globalization with Jaffry coming on board and Harsha coming on Board, our CTO. And then on Life Sciences, we have gone down the track to say, yeah, there’s buyers for that, too. It’s a little bit more complex to untangle it, but it’s not growing right now, but we believe so much in the team and the asset, we know it’s going to grow in the future.
And I can’t do everything I want, I have to sequence things and so if I had to prioritize what the sequence, it would be get enterprise to scale, trade the Provider assets to the right partner that not only provides money but strategic value. And then in Life Sciences, being more of a position of strength by showing growth, because we think that the team will achieve the growth and if we are not getting the growth right now, it’s more macro issues than capability issue.
Eric Percher: Great color. Thank you.
Jeff Arnold: Sure.
Operator: The next question is a follow-up from Richard Close of Canaccord. Please go ahead.
Richard Close: Yeah. Maybe just a follow-up on that last set of questions. So, Jeff, in terms of the sequence that you just mentioned. So should we think about like 2023 — from a time line perspective, should we think about this being essentially a clean story as we roll into 2024? Just maybe some thoughts on the timing of finalizing
Jeff Arnold: Yeah.
Richard Close: what you are trying to do here with the review and offload
Jeff Arnold: Yeah. Yeah.
Richard Close: offloading and whatnot?
Jeff Arnold: Yeah. That’s a great question. So basically if you think about what our goal is from today is like we wanted to convey the confidence of the topics that we have been talking about. Here’s where enterprise is, here’s where Life Sciences is, here’s where Provider is. We wanted to convey with confidence that we have got financial advisers and we have active conversations and this is a daily thing that we are working on, figuring out how do we take these puzzle pieces and unlock value in the best way and while that’s happening is, there’s a huge focus on profitability. And so we are taking — we have made big investments in sales, we have made big investments in products and now we have to realize that cost savings.
So we can improve our EBITDA profile and others and so that’s happening. And we have set a goal to say, hey, we are sitting here, we have basically put guidance out that says we are booked, and yes, we believe that there are all kinds of good things are going to happen throughout the year, like they always do, but this is what we are going with is what we are booked and that we are going to conclude the strategic review as quickly as we can. And we are not — right now, if you said, well, where are you? I would say, we are almost in the red zone, like — we are almost in the red zone and it will definitely conclude in 2023. And we are working to give to finalize it so that we can give you complete clarity as we make progress throughout the year, but more importantly into the future.
Richard Close: Okay. Thank you.
Jeff Arnold: Sure.
Operator: This concludes our question-and-answer session, as well as the conference. Thank you for attending today’s presentation. You may now disconnect.
